Chief Medical Officer, Office of Cardiovascular Devices
U.S. Food and Drug Administration
Silver Spring, Maryland, United States
Andrew Farb, M.D. is the Chief Medical Officer in the Office of Cardiovascular Devices at FDA’s Center for Devices and Radiological Health (CDRH). He graduated from Dartmouth College (B.A.) and Cornell University Medical College (M.D.). He completed a fellowship in clinical cardiology at The New York Hospital–Cornell University Medical Center. Dr. Farb is board-certified in Internal Medicine and Cardiovascular Diseases. He has research interests in and multiple publications on cardiovascular pathology, coronary atherosclerosis and mechanisms of thrombosis, coronary artery interventions, and structural heart disease. He joined the FDA in 2004, where he has concentrated on clinical studies for interventional cardiology, structural heart, and peripheral vascular devices. Dr. Farb co-authored FDA’s Early Feasibility Study (EFS) Guidance document, and he is the Co-Leader of CDRH’s EFS Program.
No relationships to disclose
Discussion: Priorities for Structured DEI Enhancement in Shock Studies
Friday, March 8, 2024
3:05 PM – 3:45 PM ET
Discussion: What Directions and Working Groups Best Fit Shock Evidence Priorities for 2024?
Friday, March 8, 2024
5:45 PM – 6:30 PM ET
Saturday, March 9, 2024
4:05 PM – 4:30 PM ET
Overview Discussion, Comments & Next Steps
Saturday, March 9, 2024
6:40 PM – 7:00 PM ET
FDA Valve and Structural Innovations Town Hall [Non-CME]
Monday, March 11, 2024
2:00 PM – 6:00 PM ET
Tuesday, March 12, 2024
8:00 AM – 12:30 PM ET
THE MEDICAL DEVICE INNOVATION LANDSCAPE: NAVIGATING NOVEL DEVICES THROUGH THE PROCESS
Tuesday, March 12, 2024
8:00 AM – 9:30 AM ET
Early Feasibility Study and Breakthrough Devices Programs: FDA Update
Tuesday, March 12, 2024
8:00 AM – 8:08 AM ET
Panel Discussion: Innovative Technology Headwinds and Tailwinds
Tuesday, March 12, 2024
8:55 AM – 9:30 AM ET